Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts

Market Focus

05/29

On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.

The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.

Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.

Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1188168589"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188168589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188168589?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188168589","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts","media":"Market Focus","content":"<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Ascentage Pharma Rises 6.35% in Regular Trading, B-Marker Removal Milestone Combined with ASCO Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.</p><p>The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.</p><p>Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.</p><p>Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1188168589","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188168589","pubTimestamp":1780026619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"异动快讯|亚盛医药常规交易涨6.35%B标移除里程碑叠加ASCO催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"On May 29, Ascentage Pharma rose 6.35% in regular trading, trading at 39.96 HKD/share, with trading volume of approximately 43.18 million HKD.The rally was driven by a dual catalyst. The company received approval from the Hong Kong Stock Exchange to remove the B marker from its stock code effective June 1, after meeting the market capitalization and revenue requirements under Listing Rule 8.05. The milestone was underpinned by its core products Nerlynx (olverembatinib) and lisaftoclax generating over 500 million HKD in revenue. Historically, 18A companies that achieved B-marker removal have seen meaningful valuation re-rating.Simultaneously, the ASCO Annual Meeting officially opened on May 29, with six of the company's clinical studies selected for presentation, including three rapid oral reports covering olverembatinib, lisaftoclax, and alrizomadlin. Financial results for the prior year showed revenue of 574 million RMB, with market capitalization exceeding 10 billion HKD.Within the Biotechnology sector, broad strength was evident. Among individual stocks, Innovent Biologics up 10.29%, Akeso up 7.25%, 3SBio up 4.99%, RemeGen up 3.23%, BeiGene up 1.54%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}